Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about finding a cheaper source for RU58841, with a suggestion to use Chemyo. One user suggests that RU58841 may not be necessary.

Ordering pyrilutamide and minoxidilmax's quality. Seeking good source for purchase.

Finasteride, minoxidil, and derma rolling are currently the best treatments for hair loss. New treatments like TDM-105795, GT20029, PP405, HMI 115, Tsuji, Scube 3, RU, JW0061, Topilutamide, and verteporfin show promise but have uncertain timelines.

The user shared progress pictures after three months of using RU58841, finasteride, and OM (oxidative stress modulators) for hair loss treatment. They haven't noticed much change but are seeking feedback on their results.

PP405 is a new hair loss treatment advancing quickly in trials, generating excitement and skepticism about its effectiveness and marketing claims. Some see it as a potential alternative to minoxidil and finasteride, but concerns about long-term effects and the need for DHT blockers persist.

Hair loss treatments discussed: GT 20029, Pyrilutamide, Minoxidil, Finasteride, and Dutasteride. Some believe Dutasteride will replace Finasteride.

A user shared a 3-month hair regrowth progress using minoxidil and microneedling. They also use rosemary oil and plan to continue treatment for at least 6-9 more months.

A clinical trial for hair loss treatments involving Minoxidil, Finasteride, and RU58841, and when the results of the trial will be available.

AMP-303, a new injectable treatment for androgenetic alopecia, showed promising results in increasing hair count and density with minimal side effects. The treatment demonstrated significant hair regrowth and durability, offering new hope for those with hair loss.

The conversation is about using Verteporfin with microneedling as a potential hair loss treatment that may regenerate hair follicles with minimal scarring. There are concerns about the optimal dosage and the DHT sensitivity of the new follicles.

Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.

Ordering Pyrilutamide from Minoxidilmax to use as an experimental topical treatment for hair loss, with discussion of the carrier used in trials and encouragement from other users.

A new hair loss treatment, pp405, may regrow hair better than finasteride and minoxidil, with potential availability by 2028. However, there is skepticism about its effectiveness and commercialization timeline.

A user is advocating for Phase 3 trials of the hair loss treatment PP405 to be conducted in Germany, citing benefits like a diverse patient base and faster access for European patients. Despite skepticism about the petition's influence, the user believes it can demonstrate significant interest and potentially influence strategic decisions.

The conversation is about someone seeking information on long-term users of CB-03-01 for hair loss, having experienced negative side effects from finasteride and facing rapid hair thinning.

The conversation is about testing the effectiveness of RU58841 for hair loss, with the user planning to increase their dose to 30 mg per day along with 20 mg of Minoxidil. The test results showed approximately 70 mg/ml, which the user considers a good result.

The user is trying RU58841, oral minoxidil, and dermarolling to combat hair loss caused by increased scalp testosterone after using finasteride and dutasteride. They plan to document their results.

Users discuss finding reliable sources for RU58841, focusing on lab tests, batch consistency, and community reputation. Some mention using alternatives like pyrilutamide.

User seeks participants for Verteporfin group buy. Verteporfin, FDA approved, may regenerate hair follicles and sweat glands through heavy microneedling.

KX-826 hair loss treatment completed trials with mild side effects. GT20029 may be ultimate cure, destroying androgen receptors causing baldness.

The user is considering RU58841 and has been using dutasteride since age 17. They are seeking affordable SARD options, mentioning ASC-J9, GT20029, and AH001.

The conversation is about whether the phase 2 results for pyrilutamide, a potential hair loss treatment, were presented at a dermatology convention and inquiries about the completion of phase 3 trials. Specific treatments mentioned include pyrilutamide.

RU58841 worsened hair condition, causing thinning and unusual patterns. The user stopped using it two months ago but hasn't seen recovery, and there's speculation about androgen receptor upregulation.

PP405 is a potential new hair loss treatment that works through metabolic pathways rather than hormonal ones, with an estimated market release between late 2027 and 2029. Current alternatives to finasteride include minoxidil, pyralutamide, fluridil, and RU58841, with hair transplants also being a viable option.

The user is seeking advice for the best topical treatment to combat their ongoing hair loss, despite already using oral dutasteride, RU-58841, and minoxidil. They are considering adding CB-03-01 or topical Spiro to their regimen to lower testosterone levels at the follicles.

Cosmo Pharmaceuticals has enrolled about 850 out of 1400 patients for their phase 3 clinical trials of clascoterone (Breezula) and claims to be on schedule. The conversation is about hair loss treatments.

Kintor plans to release pyrilutamide foam and a plant-based Koshine by year-end, with GT20029 progressing in their pipeline. Users are pleased about the absence of propylene glycol (PG) in the new products.

The conversation is about accessing and purchasing RU58841 or Pyrilutamide for hair loss treatment, with mentions of alternatives like Breezula. Users discuss price differences in various countries and suggest websites like rudirect.com for purchasing.

The user Consistent-Gene1334 shared their positive results in regrowing hair by using topical minoxidil and oral finasteride. Other users in the conversation praised the results and discussed the effectiveness of these treatments for diffuse thinning.

User reports 3-month progress using daily 1mg finasteride, 0.5ml minoxidil (2x daily), 0.5ml dutasteride, and derma rolling 0.5mm 1-2 times per week. They see increased density on crown and top of head, slight progress in corners and temples, and recently added cosmerna.